Sucampo Pharmaceuticals Company Profile (NASDAQ:SCMP)

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals logoSucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom. It offers AMITIZA for the treatment of constipation and RESCULA for the lowering of intraocular pressure (IOP). Its products under development include cobiprostone, RTU-1096 and RTU-009.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SCMP
  • CUSIP: 86490910
Key Metrics:
  • Previous Close: $11.75
  • 50 Day Moving Average: $11.77
  • 200 Day Moving Average: $12.86
  • 52-Week Range: $42,818,000.00 - $9.59
  • Trailing P/E Ratio: 39.70
  • Foreward P/E Ratio: 6.99
  • P/E Growth: 0.69
  • Market Cap: $503.11M
  • Outstanding Shares: 42,818,000
  • Beta: 1.74
  • Net Margins: 6.29%
  • Return on Equity: 44.19%
  • Return on Assets: 10.98%
  • Debt-to-Equity Ratio: 1.36%
  • Current Ratio: 3.56%
  • Quick Ratio: 3.19%
Additional Links:
Companies Related to Sucampo Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Sucampo Pharmaceuticals (NASDAQ:SCMP) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $18.29 (55.62% upside)

Analysts' Ratings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
DateFirmActionRatingPrice TargetDetails
12/22/2016MizuhoUpgradeNeutral -> Buy$16.00View Rating Details
11/15/2016Maxim GroupBoost Price TargetBuy$17.00 -> $19.00View Rating Details
11/11/2016Jefferies Group LLCReiterated RatingHold$14.00 -> $16.00View Rating Details
9/7/2016Northland SecuritiesInitiated CoverageOutperform$15.00View Rating Details
7/12/2016Roth CapitalReiterated RatingBuyView Rating Details
5/5/2016WallachBeth CapitalUpgradeHold -> Buy$16.00View Rating Details
5/4/2016GuggenheimReiterated RatingBuy$29.00View Rating Details
3/17/2016Leerink SwannReiterated RatingMarket Perform$17.00View Rating Details
11/6/2015HC WainwrightLower Price Target$36.00 -> $28.00View Rating Details
5/7/2015Cantor FitzgeraldDowngradeBuy -> Hold$18.00View Rating Details
3/2/2015Credit Suisse GroupDowngradeNeutral -> Underperform$10.00 -> $13.00View Rating Details
(Data available from 2/26/2015 forward)


Earnings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016Q316$0.26$0.28$51.30 million$57.90 millionViewListenView Earnings Details
8/3/2016Q216$0.22$0.23$48.33 million$52.00 millionViewListenView Earnings Details
5/4/2016Q116$0.19$0.21$44.11 million$47.20 millionViewListenView Earnings Details
3/8/2016Q415$0.19$0.43$42.72 million$55.40 millionViewListenView Earnings Details
11/4/2015Q315$0.18$0.16$36.18 million$33.50 millionViewListenView Earnings Details
8/5/2015Q215$0.15$0.21$31.90 million$34.90 millionViewListenView Earnings Details
5/6/2015Q114$0.14$0.14$30.19 million$29.50 millionViewListenView Earnings Details
3/4/2015Q413$0.17$0.21$37.23 million$37.80 millionViewListenView Earnings Details
11/6/2014Q313$0.04$0.03$26.11 million$31.50 millionViewListenView Earnings Details
8/5/2014Q213$0.03$0.04$24.06 million$24.10 millionViewListenView Earnings Details
5/7/2014Q113$0.04$0.02$24.19 million$22.20 millionViewListenView Earnings Details
2/26/2014Q4($0.04)$0.06$22.75 million$24.50 millionViewListenView Earnings Details
3/13/2013Q4 2012$0.12$0.32$32.21 million$34.90 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Current Year EPS Consensus Estimate: $1.22 EPS
Next Year EPS Consensus Estimate: $1.68 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$0.19$0.26$0.21
Q2 20165$0.20$0.29$0.25
Q3 20164$0.25$0.32$0.28
Q4 20164$0.36$0.50$0.43
Q1 20171$0.32$0.32$0.32
Q2 20171$0.38$0.38$0.38
Q3 20171$0.50$0.50$0.50
Q4 20171$0.61$0.61$0.61
(Data provided by Zacks Investment Research)


Dividend History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Insider Ownership Percentage: 3.31%
Institutional Ownership Percentage: 41.56%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016Daniel P GetmanDirectorSell20,000$16.86$337,200.00View SEC Filing  
11/29/2016Peter GreenleafCEOSell200,000$16.84$3,368,000.00View SEC Filing  
11/28/2016Matthias AlderEVPSell150,000$16.00$2,400,000.00View SEC Filing  
11/15/2016Andrew P SmithCFOSell1,766$15.58$27,514.28View SEC Filing  
8/28/2015Daniel P. GetmanDirectorSell30,000$28.14$844,200.00View SEC Filing  
7/20/2015Thomas J KnappInsiderSell64,528$23.43$1,511,891.04View SEC Filing  
3/12/2015William AshtonDirectorSell55,762$17.55$978,623.10View SEC Filing  
3/11/2015Anthony C CelesteDirectorSell65,966$17.34$1,143,850.44View SEC Filing  
12/16/2014Cary J ClaiborneCFOSell50,000$12.91$645,500.00View SEC Filing  
12/15/2014Cary J ClaiborneCFOSell7,100$12.89$91,519.00View SEC Filing  
8/7/2014Sachiko KunoMajor ShareholderSell181,727$6.28$1,141,245.56View SEC Filing  
8/4/2014Ryuji UenoMajor ShareholderSell140,873$6.02$848,055.46View SEC Filing  
7/31/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/30/2014S&R Technology Holdings, LlcMajor ShareholderSell300$6.25$1,875.00View SEC Filing  
7/25/2014Ryuji UenoMajor ShareholderSell16,155$6.26$101,130.30View SEC Filing  
7/23/2014Ryuji UenoMajor ShareholderSell5,845$6.29$36,765.05View SEC Filing  
7/22/2014S&R Technology Holdings, LlcMajor ShareholderSell2,500$6.25$15,625.00View SEC Filing  
7/21/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/18/2014S&R Technology Holdings, LlcMajor ShareholderSell15,000$6.27$94,050.00View SEC Filing  
4/29/2014S&R Technology Holdings, Llcmajor shareholderSell113,600$6.65$755,440.00View SEC Filing  
4/25/2014Sachiko Kunomajor shareholderSell118,700$6.69$794,103.00View SEC Filing  
3/18/2014Gayle DolecekDirectorSell1,200$8.03$9,636.00View SEC Filing  
2/27/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
1/17/2014Ryuji UenoCEOSell360,000$10.36$3,729,600.00View SEC Filing  
1/7/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
10/16/2013Sachiko KunoMajor ShareholderSell360,000$6.35$2,286,000.00View SEC Filing  
9/18/2013Ryuji UenoCEOSell38,462$5.69$218,848.78View SEC Filing  
9/3/2013Ryuji UenoCEOSell38,462$5.59$215,002.58View SEC Filing  
8/19/2013Ryuji UenoCEOSell38,462$6.04$232,310.48View SEC Filing  
8/6/2013Sachiko Kunomajor shareholderSell38,462$6.21$238,849.02View SEC Filing  
7/24/2013Ryuji UenoCEOSell38,462$6.52$250,772.24View SEC Filing  
7/9/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.48$249,233.76View SEC Filing  
6/24/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.61$254,233.82View SEC Filing  
6/10/2013Sachiko KunoMajor ShareholderSell38,462$7.29$280,387.98View SEC Filing  
5/28/2013Ryuji UenoCEOSell38,462$8.79$338,080.98View SEC Filing  
5/21/2013Cary J ClaiborneCFOSell4,640$9.52$44,172.80View SEC Filing  
5/20/2013Stanley G MieleSVPSell6,400$9.60$61,440.00View SEC Filing  
5/16/2013Stanley G MieleSVPSell48,600$9.67$469,962.00View SEC Filing  
5/15/2013Timothy I MaudlinDirectorBuy32,870$9.82$322,783.40View SEC Filing  
5/13/2013Sachiko KunoMajor ShareholderSell38,462$9.27$356,542.74View SEC Filing  
2/4/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$5.22$200,771.64View SEC Filing  
12/26/2012S&R Technology Holdings, LlcMajor ShareholderSell20,262$5.01$101,512.62View SEC Filing  
11/27/2012Sachiko KunoMajor ShareholderSell12,205$5.00$61,025.00View SEC Filing  
11/13/2012Sachiko KunoMajor ShareholderSell11,962$5.00$59,810.00View SEC Filing  
11/1/2012Sachiko KunoMajor ShareholderSell37,595$5.06$190,230.70View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Sucampo Pharmaceuticals (NASDAQ:SCMP)
News IconSucampo Pharmaceuticals Inc (NASDAQ:SCMP) Stock Technicals Hit Weakness (NASDAQ:SCMP) - February 24 at 9:38 PM
News IconThe Way Analysts See Sucampo Pharmaceuticals, Inc. (SCMP) (NASDAQ:SCMP) - February 24 at 9:38 PM
News IconThe Sucampo Pharmaceuticals Inc. (SCMP) Rating Increased to Buy at the Mizuho (NASDAQ:SCMP) - February 24 at 9:38 PM logoSucampo Announces Fourth Quarter and Full Year 2016 Earnings Call (NASDAQ:SCMP) - February 23 at 7:52 PM
News IconAre Analysts Optimistic About Where Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is Heading? - Winfield Review (NASDAQ:SCMP) - February 23 at 8:07 AM logoSucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Global Healthcare Conference (NASDAQ:SCMP) - February 9 at 7:04 AM
News IconIs Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) in Overbought Territory? - The Oracle Examiner (NASDAQ:SCMP) - February 4 at 12:38 AM
News IconSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) showed P/E ratio of 36.97 - The Newburgh Press (NASDAQ:SCMP) - February 4 at 12:38 AM logoMylan (MYL) Gets Favorable Verdict for Copaxone in the US (NASDAQ:SCMP) - January 31 at 10:43 PM
News IconEye on Technicals for Sucampo Pharmaceuticals Inc. (SCMP) - Sherwood Daily (NASDAQ:SCMP) - January 29 at 8:11 AM
News IconEarnings in Full Force, Analysts Take Aim at Sucampo ... - Wall Street Beacon (NASDAQ:SCMP) - January 27 at 2:54 AM
News IconStock Trading Analysis on Sucampo Pharmaceuticals, Inc. (SCMP ... - Highland Mirror (NASDAQ:SCMP) - January 27 at 2:53 AM
News IconStock Target Review on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Shares (NASDAQ:SCMP) - January 26 at 4:45 AM
News IconThe Key Figures To Watch From Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Earnings (NASDAQ:SCMP) - January 26 at 4:45 AM logoFirst Week Of September 15th Options Trading For Sucampo Pharmaceuticals (SCMP) (NASDAQ:SCMP) - January 25 at 4:24 AM logoGilead (GILD) HCV Therapy Application Validated in Europe (NASDAQ:SCMP) - January 23 at 8:04 PM
News IconDrug Makers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Sucampo Pharma, and Pernix Therapeutics (NASDAQ:SCMP) - January 20 at 11:53 PM
News IconStock Momentum Skidding to a Halt For Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) - Wall Street Beacon (NASDAQ:SCMP) - January 18 at 1:09 AM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) - Wall Street Beacon (NASDAQ:SCMP) - January 17 at 8:07 PM
News IconShares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Sees Large Inflow of Net Money Flow - Highland Mirror (NASDAQ:SCMP) - January 17 at 8:07 PM
News IconSucampo Pharmaceuticals Inc SCMP Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:SCMP) - January 17 at 12:24 PM featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals (NASDAQ:SCMP) - January 17 at 12:24 PM
News IconStock Checkup: Technical Watch on Sucampo Pharmaceuticals Inc. (SCMP) - Sherwood Daily (NASDAQ:SCMP) - January 16 at 1:32 PM logoGo Driehaus Way: 5 Momentum Picks (NASDAQ:SCMP) - January 9 at 8:59 AM
News IconSen. Cruz and Rep. DeSantis introduce congressional term limit bill (NASDAQ:SCMP) - January 5 at 6:31 AM
News IconRevenue Growth Analysis of Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NASDAQ:SCMP) - January 5 at 6:31 AM logoWhy Sucampo Pharmaceuticals (SCMP)Could Be an Impressive Growth Stock (NASDAQ:SCMP) - January 5 at 6:31 AM logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive (NASDAQ:SCMP) - December 29 at 8:33 AM logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:SCMP) - December 29 at 12:35 AM
News IconCan This Stock Gain Traction: Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) - Prospect Journal (NASDAQ:SCMP) - December 27 at 9:17 AM logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Announces Its New Debt Offering Of Convertible Notes - Market Exclusive (NASDAQ:SCMP) - December 24 at 8:07 AM logoAnalyst Upgrades – Sucampo Pharmaceuticals (NASDAQ:SCMP) Stock Gets Upgraded By Mizuho from Neutral to Buy (NASDAQ:SCMP) - December 23 at 7:53 PM
News IconNoticeable Stock: Enterprise Products Partners L.P. (NYSE:EPD), Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) - The Newburgh Press (NASDAQ:SCMP) - December 23 at 1:08 AM logoSucampo Pharmaceuticals : Announces Pricing of $260.0 Million 3.25% Convertible Senior Notes due 2021 (NASDAQ:SCMP) - December 22 at 8:07 PM logoSucampo Pharma upgraded by Mizuho (NASDAQ:SCMP) - December 22 at 8:07 PM logoSucampo Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCMP) : December 22, 2016 (NASDAQ:SCMP) - December 22 at 8:07 PM
News IconSucampo Pharmaceuticals, Inc. (SCMP) Announces Its New Debt Offering Of Convertible Notes (NASDAQ:SCMP) - December 22 at 2:46 PM
News IconCompany Shares in Review: Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) - OIB News (NASDAQ:SCMP) - December 22 at 3:43 AM logoSucampo Pharmaceuticals Inc. (SCMP) Is Losing Ground On Offering News (NASDAQ:SCMP) - December 21 at 10:42 PM logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Files An 8-K Regulation FD Disclosure (NASDAQ:SCMP) - December 21 at 10:42 PM logoSucampo Pharma (SCMP) Prices $260M Convertible Senior Notes Offering (NASDAQ:SCMP) - December 21 at 10:42 PM logoSucampo Announces Pricing of $260.0 Million 3.25% Convertible Senior Notes due 2021 (NASDAQ:SCMP) - December 21 at 10:42 PM logo5:57 am Sucampo Pharma prices $260 mln of 3.25% convertible senior notes due 2021 in a private placement to qualified institutional buyers (NASDAQ:SCMP) - December 21 at 10:42 PM logoSucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : December 21, 2016 (NASDAQ:SCMP) - December 21 at 10:42 PM logoHere's Why Sucampo Pharmaceuticals Is Down Over 20% Today (NASDAQ:SCMP) - December 20 at 3:16 PM
News IconMF Rank Review for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) - Business Daily Leader (NASDAQ:SCMP) - December 20 at 2:33 PM logoSucampo Pharma (SCMP) to Offer $225M in Convertible Senior Notes - (NASDAQ:SCMP) - December 20 at 2:33 PM logoSucampo Announces Proposed Convertible Senior Note Offering (NASDAQ:SCMP) - December 20 at 2:33 PM logo4:02 pm Sucampo Pharma announces its intention to offer $225.0 million principal amount of convertible senior notes due 2021 in a private offering (NASDAQ:SCMP) - December 20 at 2:33 PM logoSUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:SCMP) - December 20 at 2:33 PM


What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

Where is Sucampo Pharmaceuticals' stock going? Where will Sucampo Pharmaceuticals' stock price be in 2017?

8 equities research analysts have issued 12 month target prices for Sucampo Pharmaceuticals' stock. Their predictions range from $15.00 to $29.00. On average, they anticipate Sucampo Pharmaceuticals' share price to reach $18.29 in the next year.

When will Sucampo Pharmaceuticals announce their earnings?

Sucampo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

What are analysts saying about Sucampo Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:

  • According to Zacks Investment Research, "Sucampo is focused on expanding its sole marketed product, Amitiza’s label and penetrating into new markets. Amitiza's solid prescription growth so far this year demonstrates persistently robust demand. Moreover, the company’s collaborations with firms like Takeda and Mylan for the commercialization of Amitiza is a big positive. In addition, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. However, Sucampo’s dependence on Amitiza for growth is concerning. Any decline in Amitiza's sales will adversely impact the top-line. Moreover, it is no stranger to pipeline setbacks. Shares of the company have underperformed the Medical-Drugs industry in the past one year." (2/21/2017)

  • Jefferies Group LLC analysts commented, "SCMP reported Q4 EPS of $0.23 (vs $0.19 JEFe) on revs of $55M – which included 2 months of R-Tech contributions ($11.8M) despite a Dec 7 close and a $5M payment from MYL. Excluding these items, revs reached $38.6M (+36% Y/Y) – slightly ahead of our $37.9M est. Mgt reaffirmed its FY16 guidance and sees 5 key data readouts this year. We remain constructive on mgt’s ability to deliver value creating M&A – which remains the key to significant share appreciation. Despite Managed Care Change, Amitiza Still Poised for Low Double Digit Growth: While Amitiza lost preferred formulary status at Caremark on Jan 1, partner Takeda deployed a zero copay card in late FY15 to bolster patient access. Rxs have stabilized, posting mid-single digit Y/Y gains YTD (vs 9.8% in 4Q15). Mgt indicated that they are somewhat insulated from potential pricing headwinds as SCMP’s contract with Takeda caps its GtN exposure at 20%. Including a 5% price increase on Jan 1, Amitiza remains poised for low double digit growth this year. With an Amitiza settlement (FTF Par) already in place, SCMP plans to vigorously defend its IP from Dr. Reddy’s." (3/9/2016)

  • Maxim Group analysts commented, "Sucampo reported 4Q revenues of $55M vs. $33M in the prior quarter, with the increase being driven by both the R-Tech Ueno acquisition and strong Amitiza revenues (20% plus). GAAP net income was reported $10M or $0.23 per share. On an adjusted (Non-GAAP) basis the company had $19M in net income." (3/9/2016)

Who owns Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Ryuji Uen (23.00%), Sachiko Kun (23.00%), Sachiko Kuno Foundation, Inc (5.20%), Dimensional Fund Advisors LP (3.64%), Renaissance Technologies LLC (3.41%) and Royce & Associates LP (1.83%). Company insiders that own Sucampo Pharmaceuticals stock include Andrew P Smith, Anthony C Celeste, Daniel P Getman, Matthias Alder, Peter Greenleaf, Thomas J Knapp and William Ashton.

Who sold Sucampo Pharmaceuticals stock? Who is selling Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Menta Capital LLC, GSA Capital Partners LLP, AQR Capital Management LLC, FMR LLC, Pacad Investment Ltd. and Renaissance Group LLC. Company insiders that have sold Sucampo Pharmaceuticals stock in the last year include Andrew P Smith, Daniel P Getman, Matthias Alder and Peter Greenleaf.

Who bought Sucampo Pharmaceuticals stock? Who is buying Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Stonepine Capital Management LLC, Royce & Associates LP, State Street Corp, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Tudor Investment Corp Et Al and Clark Capital Management Group Inc..

How do I buy Sucampo Pharmaceuticals stock?

Shares of Sucampo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sucampo Pharmaceuticals stock cost?

One share of Sucampo Pharmaceuticals stock can currently be purchased for approximately $11.75.

Sucampo Pharmaceuticals (NASDAQ:SCMP) Chart for Sunday, February, 26, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Earnings History Chart

Earnings by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Dividend History Chart

Dividend Payments by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Last Updated on 2/26/2017 by Staff